Lmr Partners LLP Legend Biotech Corp Transaction History

Lmr Partners LLP

$10.9 Billion
Q3 2024

A detailed history of Lmr Partners LLP transactions in Legend Biotech Corp stock. As of the latest transaction made, Lmr Partners LLP holds 124,400 shares of LEGN stock, worth $4.98 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

124,400

Previous 127,000 2.05%

Holding current value

$4.98 Million

Previous $5.62 Million 7.79%

% of portfolio

0.06%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$43.55 - $59.88 $113,229 - $155,688	-2,600 Reduced 2.05%	124,400 $6.06 Million
Q2 2024 Aug 14, 2024	BUY	$39.5 - $57.22 $991,450 - $1.44 Million	25,100 Added 24.63%	127,000 $5.62 Million
Q1 2024 May 15, 2024	BUY	$55.06 - $69.99 $836,912 - $1.06 Million	15,200 Added 17.53%	101,900 $5.72 Million
Q4 2023 Feb 14, 2024	BUY	$57.25 - $69.74 $675,378 - $822,722	11,797 Added 15.75%	86,700 $5.22 Million
Q3 2023 Nov 14, 2023	BUY	$63.16 - $76.5 $170,721 - $206,779	2,703 Added 3.74%	74,903 $5.03 Million
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $860,808 - $1.4 Million	-18,600 Reduced 20.48%	72,200 $4.98 Million
Q1 2023 May 15, 2023	BUY	$43.42 - $57.37 $846,690 - $1.12 Million	19,500 Added 27.35%	90,800 $4.38 Million
Q4 2022 Feb 14, 2023	BUY	$38.8 - $55.46 $582,000 - $831,900	15,000 Added 26.64%	71,300 $3.56 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $55.0 $1.1 Million - $1.8 Million	32,749 Added 139.06%	56,300 $3.1 Million
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $404,811 - $628,749	13,050 Added 124.27%	23,551 $856,000
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $432,011 - $598,346	10,501 New	10,501 $489,000

Others Institutions Holding LEGN

# of Institutions

205

Shares Held

74.5M

Call Options Held

371K

Put Options Held

387K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.7B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account